Omnicell

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Omnicell reports robust Q4 earnings, eyes Advanced Services growth

Omnicell's Q4 2022 earnings call highlighted a strong financial performance, cost-saving initiatives, and strategic priorities for 2023. The company aims to drive growth through Advanced Services expansion, while navigating challenges such as market conditions and regulatory impacts. By focusing on operational efficiency and prudent financial management, Omnicell positions itself for sustainable growth and profitability.

Omnicell surpasses Q1 revenue targets, eyes automation for growth

Omnicell's Q1 2023 earnings call showcased robust financial performance, strategic partnerships, and cost containment efforts. The company is well-positioned to capitalize on the growing demand for automation in healthcare.

Omnicell surpasses Q2 expectations, focuses on AI strategy growth

Omnicell's Q2 performance exceeded expectations, driven by strong revenues and margins.
The company's strategic strengths lie in customer wins, AI focus, and margin management.
Challenges include market dynamics and the need for ongoing adjustments.
Opportunities for growth include raised guidance, AI strategy development, and CMS impact.

Omnicell reports Q3 earnings, faces challenges but eyes growth opportunities

Omnicell's Q3 2023 performance reflects solid total revenues, EBITDA, and EPS, with market challenges impacting bookings and product lines. The company's strengths include customer wins, profitability, and strategic growth initiatives.
Challenges include revenue impact from reduced bookings, point-of-care revenue decline, and pipeline deal deferrals. Opportunities exist in Advanced Services growth, market expansion, and cost management strategies.
Omnicell's focus on profitability, revenue growth, and customer value delivery positions it for future success. The company's strategic actions and financial outlook indicate a proactive approach to addressing challenges and seizing opportunities.

Omnicell reports Q4 revenue decline but sees growth opportunities ahead

Omnicell's Q4 2023 performance saw revenue decline but highlighted strategic wins and a focus on operational optimization.
The company's strengths lie in customer engagement, product upgrades, and expansion into new markets.
Challenges include industry costs and regulatory hurdles, but opportunities exist in market growth and service enhancements.
Overall, Omnicell remains optimistic about future demand and revenue potential, with a conservative outlook for Q1.

Omnicell surpasses Q1 revenue targets, exits product line for value

Omnicell's Q1 2024 earnings call showcased strong performance exceeding guidance, with a focus on cost management and strategic initiatives. The company announced plans to exit an international product line to improve shareholder value. Opportunities lie in the growth of the XT Amplify program and EnlivenHealth brand, despite challenges in revenue decline and operational decisions.

Omnicell reports robust Q3 earnings, eyes growth in healthcare solutions

Omnicell's Q3 2024 performance reflects strong revenue growth and operational resilience in healthcare solutions.
The company's strategic focus on customer-centricity and innovation positions it for sustained success.
Challenges in product revenue timing and cost optimization require ongoing attention for operational efficiency.
Opportunities in expanding services and market positioning offer avenues for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Fort Worth, TX.

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Acquire ReCept

Omnicell to Acquire ReCept

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Present at Upcoming Investor Conferences

Omnicell to Present at Upcoming Investor Conferences

Omnicell (OMCL) could produce exceptional returns because of its solid growth attributes.

3 Reasons Growth Investors Will Love Omnicell (OMCL)

Investors are optimistic about Omnicell (OMCL) owing to its better-than-expected results in the third quarter and robust segmental performance.

Here's Why You Should Add Omnicell (OMCL) To Your Portfolio

NextGen Healthcare Inc

NXGN vs. OMCL: Which Stock Is the Better Value Option?

NXGN vs. OMCL: Which Stock Should Value Investors Buy Now?

Omnicell (OMCL), Fresenius Kabi collaborate to offer safe and efficient dispensing of controlled substances across hospitals and health systems in the United States.

Omnicell (OMCL) Inks New Deal to Manage Controlled Substances

MOUNTAIN VIEW, Calif. & LAKE ZURICH, Ill.--(BUSINESS WIRE)--Omnicell and Fresenius Kabi Collaborate to Enhance Management of Controlled Substances in U.S. Hospitals

Omnicell and Fresenius Kabi Collaborate to Enhance Management of Controlled Substances in U.S. Hospitals

Growth across both the operating segments of Omnicell (OMCL) contributes to Q3 top-line growth.

Omnicell (OMCL) Q3 Earnings Top Estimates, 2021 View Up

Omnicell, Inc.'s (OMCL) CEO Randall Lipps on Q3 2021 Results - Earnings Call Transcript

NXGN or OMCL: Which Is the Better Value Stock Right Now?

Omnicell (OMCL) delivered earnings and revenue surprises of 18.68% and 4.43%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Omnicell (OMCL) Surpasses Q3 Earnings and Revenue Estimates

Omnicell (NASDAQ:OMCL) reported its Q3 earnings results on Tuesday, November 2, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Recap: Omnicell Q3 Earnings

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Tucson VA Medical Center has chosen the Company's Central Pharmacy Dispensing Service (“CPDS”) in an effort to enhance patient safety, improve operational efficiency, and optimize inventory management for its central pharmacy operations. The Veterans Health Administra

Tucson VA Medical Center Selects Omnicell's Central Pharmacy Dispensing Service to Enhance Medication Inventory Management

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its third quarter ended September 30, 2021. GAAP Results Total GAAP revenues for the third quarter of 2021 were $296.4 million, up $82.7 million, or 38.7%, from the third quarter of 2020. The increase in GAAP revenues reflec

Omnicell Announces Financial Results for Third Quarter 2021

Henry Schein

IDEXX Laboratories

STERIS

With the pandemic raging on, testing, vaccine and therapeutic makers are witnessing huge market adoption of their COVID-related support products in Q3.

Medical Products Stock Earnings on Nov 2: IDXX, STE & More

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Omnicell (OMCL) Reports Next Week: Wall Street Expects Earnings Growth

Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Omnicell (OMCL) Soars to 52-Week High, Time to Cash Out?

Convey Holding Parent

CNVY vs. OMCL: Which Stock Is the Better Value Option?

CNVY vs. OMCL: Which Stock Should Value Investors Buy Now?

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the third quarter of 2021 before the open of the market on Tuesday, November 2, 2021. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentat

Omnicell to Release Third Quarter 2021 Financial Results on November 2, 2021

Inspire Medical Systems Inc

10X Genomics

Stocks like 10x Genomics Inc. (TXG), Omnicell, Inc. (OMCL) and Inspire Medical Systems, Inc. (INSP) are expected to gain despite pandemic-led disruptions.

Buy 3 Medical Info Systems Stocks to Brave Industry-wide Challenges

Omnicell (OMCL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Omnicell (OMCL) Soars 3.4%: Is Further Upside Left in the Stock?

FORT WORTH, Texas, Oct. 6, 2021 /PRNewswire/ -- FDS Amplicare, which builds industry-leading SaaS technology solutions that strengthen the health of retail pharmacies and their patients, today announced that it will host a webinar to help pharmacists learn how to assist patients in selecting the right Prescription Drug, Medicare Advantage and Medigap plans that support their healthcare and financial needs. Pharmacists who attend the webinar will receive tips on leveraging online tools to provide patients with important plan selection information as well as working with licensed insurance agents to make the Medicare open enrollment process easier and less stressful for patients.

FDS Amplicare Hosts Webinar to Advise Pharmacists on Assisting Customers During Medicare Open Enrollment

AutoNation

Computer Programs and Systems

Group 1 Automotive

Jiayin Group Inc - ADR

Paycom Software

There has been notable job gains in automotive, hospitality, retail, social assistance and in professional and business services through the past few months.

3 Sectors Looking Up Ahead of Q3 Earnings Despite COVID-19 Woes

With the FDS Amplicare acquisition, Omnicell (OMCL) is expected to gain from several healthcare trends, banking on its offerings of digital technologies, SaaS solutions, and tech-enabled services.

Omnicell (OMCL) New Buyout Expands Patient Engagement Suite

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Completes Acquisition of FDS Amplicare

News for Omnicell Stock (OMCL)